Microbion Corporation of Bozeman, MT, and Microbion Pharma Corp of Vancouver, BC (Microbion), a clinical-stage biopharmaceutical company, has received recommendation from the World Health Organization (WHO) for 'pravibismane' as the International Nonproprietary Name (INN) also commonly known as the generic name, for Microbion's lead broad-spectrum antimicrobial and antibiofilm agent, it was reported on Friday.
The announcement was made by Microbion.
The firm has completed Phase one and early Phase two trials of pravibismane formulated for topical and intrasurgical administration in diabetic foot ulcer infections and orthopaedic device-related infections, respectively. Microbion says that Pravibismane has broad spectrum, antibacterial efficacy against a broad range of pathogens, including multiple priority pathogens or 'superbugs' identified by the US Centers for Disease Control and Prevention (CDC). It has also demonstrated the ability to eradicate microbial biofilms.
;;;
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes